This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-9 (cancelled).

Claim 10 (withdrawn): A method for treating patients with dermatological diseases comprising topically treating said patients with said dermal CYP1A inhibitor according to claim 1.

Claim 11 (withdrawn): The method according to claim 10, wherein said dermal CYP1A is co-administered with a dermatological drug.

Claim 12 (withdrawn): The method according to claim 11, wherein said dermatological drug is retinoid.

Claim 13 (withdrawn): A method for treating patient with skin cancer comprising topically applying the dermal CYP1A inhibitor according to claim 1 to said patient with skin cancer.

Claim 14 (withdrawn): The method for treating patient with skin cancer according to claim 13, wherein said dermal CYP1A inhibitor is co-administered with retinoid.

Claim 15 (withdrawn): A dermal cytochrome P450 1A enhancer which is a free base or pharmacologically acceptable salt of at least one compound selected from the group consisting of (+)-catechin, (-)-epicatechin, (+)-epicatechin, (+)-limonene, 3-phenylpropyl acetate, apigenin, baicalein, baicalin, .beta.-myrcene, cineole, daidzein, daidzin, diosmin, ergosterol, formononetin, gallic acid, glycyrrhizin, hesperidin, isoquercitrin, kaempferol, lauryl alcohol, luteolin, luteolin-7-glycoside, narigin, nordihydroguaiaretic acid, paeoniflorin, protocatechuic acid, quercetin, quercitrin, rutin, swertiamarin, terpineol, trans-cinnamic acid, umbelliferone, and umbellic acid.

Claim 16 (withdrawn): The dermal cytochrome P450 1A (CYP1A) enhancer according to claim 14, wherein said enhancer is at least one selected from the group consisting of(-)-epicatechin, cineole, narigin, and protocatechuic acid.

Claims 17-32 (cancelled).

Claim 33 (withdrawn): A method for prolonging a therapeutic effect of a dermatological drug in a mammal comprising topically administering a dermal cytochrome P450 1A (CYP1A) inhibitor to said mammal, wherein said dermal CYP1A inhibitor is at least one selected from the group consisting of (-)-epicatechin, (+)-epicatechin, (+)-limonene, 3-phenylpropyl acetate, apigenin, baicalein, baicalin, β-myrcene, catechin, β-naphthoflavone, cineole, daidzein, daidzin, diosmin, ergosterol, formononetin, gallic acid, genistein, glycyrrhizin, glycyrrhizic acid, hesperetin, hesperidin, isoquercitrin, kaempferol, lauryl alcohol, luteolin, luteolin-7-glycoside, narigin, nordihydroguaiaretic acid, oleanolic acid, paeoniflorin, quercitrin, rutin, swertiamarin, terpineol, trans-cinnamaldehyde, trans-cinnamic acid, umbelliferone, genkwanin, homoorientin, isovitexin, neohesperidin, wongonin, capillarisin, liquiritin, ethyl myristate, poncirin, and ursolic acid.

Claim 34 (withdrawn): The method according to claim 34, wherein said dermal CYP1A inhibitor is at least one selected from the group consisting of kaempferol, luteolin-7-glycoside, terpineol, β-naphthoflavone, and hesperetin.

Claim 35 (withdrawn): The method according to claim 33, wherein said CYP1A inhibitor inhibits enzymatic activity of a dermal cytochrome P450 1A in performing a first pass metabolism of said dermological drug on skin of said mammal.

Claim 36 (withdrawn): The method according to claim 33, wherein said dermatological drug is retinoid.

Claim 37 (withdrawn): The method according to claim 33, wherein said dermatological drug is retinoic acid.

Claim 38 (withdrawn): The method according to claim 33, wherein said CYP1A inhibitor and said dermatological drug are topically co-administered to said mammal.

Claim 39 (withdrawn): A method for preventing skin cancer in a mammal comprising topically administering a dermal cytochrome P450 1A (CYP1A) inhibitor to said mammal, wherein said dermal CYP1A inhibitor is at least one selected from the group consisting of (-)-epicatechin, (+)-epicatechin, (+)-limonene, 3-phenylpropyl acetate, apigenin, baicalein, baicalin, β-myrcene, catechin, β-naphthoflavone, cineole, daidzein, daidzin, diosmin, ergosterol, formononetin, gallic acid, genistein, glycyrrhizin, glycyrrhizic acid, hesperetin, hesperidin, isoquercitrin, kaempferol, lauryl alcohol, luteolin, luteolin-7-glycoside, narigin, nordihydroguaiaretic acid, oleanolic acid, paeoniflorin, quercitrin, rutin, swertiamarin, terpineol, trans-cinnamaldehyde, trans-cinnamic acid, umbelliferone, genkwanin, homoorientin, isovitexin, neohesperidin, wongonin, capillarisin, liquiritin, ethyl myristate, poncirin, and ursolic acid.

Claim 40 (withdrawn): The method according to claim 39, wherein said CYP1A inhibitor inhibits enzymatic activity of cytochrome P450 1A in converting a chemical into a carcinogen when said chemical is in contact with skin of said mammal.

Claim 41 (withdrawn): A method for prolonging therapeutic effect of an oral drug comprising orally administering a liver cytochrome P450 1A (CYP1A) inhibitor to said mammal, wherein said CYP1A is at least one selected from the group consisting of β-naphthoflavone, kaempferol, trans-cinnamaldehyde, and luteolin.

Claim 42 (withdrawn): The method according to claim 41, wherein said CYP1A inhibitor inhibits enzymatic activity of a liver cytochrome P450 1A in performing a first pass metabolism of said oral drug in said liver of said mammal.

Claim 43 (presently amended): A pharmaceutical composition comprising a free base or a pharmaceutically acceptable salt of ~~said~~ a dermal cytochrome P450 1A (CYP1A) inhibitor, and a carrier ~~according to claim 33~~, wherein said dermal CYP1A inhibitor is at least one selected from the group consisting of (-)-epicatechin, (+)-epicatechin, (+)-limonene, 3-phenylpropyl acetate, apigenin, baicalein, baicalin, β-myrcene, catechin, β-naphthoflavone, cineole, daidzein, daidzin, diosmin, ergosterol, formononetin, gallic acid, genistein, glycyrrhizin, glycyrrhizic acid, hesperetin, hesperidin, isoquercitrin, kaempferol, lauryl alcohol, luteolin, luteolin-7-glycoside, narigin, nordihydroguaiaretic acid, oleanolic acid, paeoniflorin, quercitrin, rutin, swertiamarin, ~~terpineol~~, trans-cinnamaldehyde, trans-cinnamic acid, umbelliferone, genkwanin, homoorientin, isovitexin, neohesperidin, wongonin, capillarisin, liquiritin, ethyl myristate, poncirin, and ursolic acid.

Claim 44 (presently amended): A~~The~~ pharmaceutical composition comprising a free base or a pharmaceutically acceptable salt of a dermal cytochrome A450 1A (CYP1A), ~~according to claim 43~~ and a carrier, wherein said dermal CYP1A inhibitor is terpineol; and wherein said pharmaceutical composition is applied to skin of a mammal together with a dermatological drug.

Claim 45 (cancelled).

Claim 46 (presently amended): The topical pharmaceutical composition according to claim 43 ~~45~~, wherein ~~said CYP1A inhibitor is terpineol and~~ said dermatological drug is retinoic acid or retinoid.

Claim 47 (previously added): The pharmaceutical composition according to claim 43, wherein said CYP1A inhibitor is in the amount of about 10% by weight of said pharmaceutical composition.

Claim 48 (new): The pharmaceutical composition according to claim 44, wherein said dermatological drug is retinoic acid or retinoid.

Claim 49 (new): A topical pharmaceutical composition comprising a free base or a pharmaceutically acceptable salt of a dermal cytochrome P450 1A (CYP1A) inhibitor, a carrier, and a dermatological drug;

wherein said dermal CYP1A inhibitor is at least one selected from the group consisting of (-)-epicatechin, (+)-epicatechin, (+)-limonene, 3-phenylpropyl acetate, apigenin, baicalein, baicalin, β-myrcene, catechin, β-naphthoflavone, cineole, daidzein, daidzin, diosmin, ergosterol, formononetin, gallic acid, genistein, glycyrrhizin, glycyrrhizic acid, hesperetin, hesperidin, isoquercitrin, kaempferol, lauryl alcohol, luteolin, luteolin-7-glycoside, narigin, nordihydroguaiaretic acid, oleanolic acid, paeoniflorin, quercitrin, rutin, swertiamarin, terpineol, trans-cinnamaldehyde, trans-cinnamic acid, umbelliferone, genkwanin, homoorientin, isovitexin, neohesperidin, wongonin, capillarisin, liquiritin, ethyl myristate, poncirin, and ursolic acid.

Claim 50 (new): The topical pharmaceutical composition according to claim 49, wherein said CYP1A inhibitor is terpineol and said dermatological drug is retinoic acid or retinoid.

Claim 51 (new): The topical pharmaceutical composition according to claim 49, wherein said CYP1A inhibitor is in the amount of about 10% by weight of said pharmaceutical composition.